CUREVAC N.V. O.N.
Commented by Stefan Feulner on May 10th, 2021 | 09:14 CEST
CureVac, Cardiol, MorphoSys - Huge sensation in the fight against Corona!
The biotechnology sector gained tremendous attention since the start of the Corona pandemic. With vaccine makers such as BioNTech or Moderna, investors have achieved returns beyond 1000% since the end of 2019. Currently, drug research against Sars-CoV-2 is in full swing. More effective and safe drugs along with vaccination and testing strategies are critical to managing the pandemic. For investors, this meant a second chance at the next tenbagger.
Read
Commented by Nico Popp on May 3rd, 2021 | 07:25 CEST
BioNTech, CureVac, Cardiol Therapeutics: In on the next blockbuster from the start
The two German companies BioNTech and CureVac, have been causing quite a stir since the outbreak of the pandemic. At first, the biotech newcomers were known only to hard-nosed investors who are used to seizing long-term opportunities and accepting initial uncertainty to do so. Even during the first months of the pandemic, it was far from clear whether BioNTech and CureVac would be successful. Only a few insiders had the right instinct early on thanks to the necessary background knowledge and are pleased with BioNTech's annual performance of 260%. But what characterizes the success of innovative biotech companies? And where are the next opportunities lurking? We outline some exciting investment stories.
Read
Commented by Stefan Feulner on April 28th, 2021 | 07:04 CEST
CureVac, PsyBio, Evotec - Revolution in the billion-dollar market!
The anxiety and limitations associated with the coronavirus pose major challenges for people suffering from depression. Officially, around 350 million people worldwide live with depression, but the number of unreported cases is significantly higher. At the moment, the number one cause of the disease is only combated with antidepressants; there are hardly any alternative treatment methods without severe side effects. A completely new field is currently emerging that could completely eclipse existing drugs, with incredible potential for the young companies.
Read
Commented by Stefan Feulner on April 20th, 2021 | 09:45 CEST
Varta, Sierra Growth, CureVac - Clear signals!
Sometimes, for various reasons, it takes longer before the positive developments of a Company are absorbed by the market and thus provide for price gains. It is currently similar to the precious metal gold, which is still in the consolidation phase. The facts such as national debt, inflation fears and the ultra-loose monetary policy of the central banks speak another clear language.
Read
Commented by Nico Popp on April 20th, 2021 | 06:50 CEST
CureVac, BioNTech, PsyBio: Yesterday's game changers - and tomorrow's?
Vaccines against the coronavirus are changing everything. People who sat anxiously at home just a few weeks ago now dare to socialize again after their injection. Even if contact restrictions still apply - the feeling of being alive is different after the vaccination. German vaccine manufacturers, in particular, have used innovative mRNA technology to create vaccines that are largely scandal-free - and offer good protection. In the slipstream, new, innovative companies are already preparing to bring the next game changers to market. For investors, this can be a rewarding environment.
Read
Commented by Stefan Feulner on April 15th, 2021 | 07:15 CEST
Alibaba, The Place Holdings, CureVac - Great opportunities lie here!
The German vaccination disaster is going into the next round. After the AstraZeneca vaccine's back and forth and the question of whether only younger people, older people or no one should be vaccinated with the vaccine, the American vaccine manufacturer Johnson & Johnson is now experiencing delivery stoppages. The return to "normality" once again seems to be a long way off. Another question to ask yourself. What will future life in the new normal look like in the hard-pressed inner cities?
Read
Commented by Stefan Feulner on March 24th, 2021 | 09:06 CET
CureVac, Scottie Resources, Newmont - Is the monetary system at its end?
There is a dangerous mix brewing in the international financial markets. With the passage of the new USD 1.9 trillion US stimulus package, whose money will be used primarily to boost consumption, inflation expectations rise. The Fed expects inflation to average 2.4% in 2021. Nevertheless, the Fed intends to continue its path of loose monetary policy, which was accelerated during the Corona Crisis, until at least 2023. In doing so, Fed Chairman Powell violates the basic principle of central banks to take preventive action against inflation. There is a threat of monetary devaluation of historic proportions.
Read
Commented by Stefan Feulner on March 12th, 2021 | 07:25 CET
CureVac, Pollux Properties, SAP - Go for the latecomers!
At the moment, a shift from technology stocks to value stocks is taking place on the global stock markets. Companies that outperformed after bottoming out in March 2020 are losing disproportionately in the current market phase. In contrast, many investors are currently betting on the supposed re-opening winners such as TUI and Lufthansa & Co. Here, several stocks have enormous catch-up potential and are lagging behind in their performance.
Read
Commented by Nico Popp on March 10th, 2021 | 09:27 CET
BioNTech, CureVac, Cardiol Therapeutics: Biotech rockets off the launchpad
We all know that health is the greatest good. But it is only the last year or so that we've become fully aware of the fact that everything changes during a pandemic. Work, family, leisure time - no area of life is not currently under the influence of Covid-19. But even if lockdown fatigue is slowly but surely setting in, investors should remain wide awake. In many sectors, the course is currently being set for the future - especially in the pharmaceutical and biotech industries. Reason enough to take a closer look at these three stocks.
Read
Commented by Stefan Feulner on February 16th, 2021 | 11:00 CET
CureVac, Desert Gold, TUI - These are the big winners!
Slowly one no longer hears the topic of the Corona Crisis. Every day there are new developments on the table. Will the lockdown be lifted, when will people be allowed to travel again, and when will retail and restaurants reopen their doors? In the first phase of the pandemic, you could identify the winners, for example, online retailers like Amazon. We should keep a close eye on which industry is benefiting or who is starting to make a comeback.
Read